Dongchi Cai^1,2,#, Jialin Ji^3,#, Chunhui Yang^1,*, Hong Cai^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.071152 - 30 December 2025

Abstract Metabolic reprogramming involving branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—is increasingly recognized as pivotal in cancer progression, metastasis, and immune modulation. This review comprehensively explores how cancer cells rewire BCAA metabolism to enhance proliferation, survival, and therapy resistance. Tumors manipulate BCAA uptake and catabolism via high expression of transporters like L-type amino acid transporter 1 (LAT1) and enzymes including branched chain amino acid transaminase 1(BCAT1), branched chain amino acid transaminase 2 (BCAT2), branched-chain alpha-keto acid dehydrogenase (BCKDH), and branched chain alpha-keto acid dehydrogenase kinase (BCKDK). These alterations sustain energy production, biosynthesis, redox homeostasis, and oncogenic… More >

Abdul Baseet Arham¹, John M. Rieth², Michael A. O’Donnell^3,*

Canadian Journal of Urology, Vol.32, No.6, pp. 605-620, 2025, DOI:10.32604/cju.2025.063632 - 30 December 2025

Abstract Background: Genitourinary (GU) sarcomas are rare soft tissue malignancies, comprising around 2% of all GU cancers. Due to their rarity, limited data exist on optimal management and long-term outcomes. This study presents a 25-year single-institution experience, evaluating clinical presentation, treatment strategies, and survival outcomes, aims to identify trends over time and potential predictors of prognosis. Methods: A retrospective review was conducted of patients aged ≥18 years diagnosed with GU sarcomas at the University of Iowa Hospitals and Clinics (1998–2023). Data on tumor subtype, staging, histopathology, treatment modalities, and survival outcomes were analyzed. Kaplan-Meier analysis estimated… More >

Rym Akrout¹, Ludovic Leloup², Khouloud Ayed¹, Fabrice Parat², Sami Zekri^3,4, Wassim Y. Almawi¹, Rahma Boughriba¹, Hanen Attia¹, Olfa Masmoudi-Kouki⁴, Hervé Kovacic^2,*, Asma Gati^1,*

Oncology Research, Vol.33, No.12, pp. 3887-3906, 2025, DOI:10.32604/or.2025.070729 - 27 November 2025

Abstract Objectives: Cisplatin (CDDP) therapy for glioblastoma (GBM) is linked with several limitations, which include poor penetration of the blood-brain barrier (BBB), systemic toxicity, and the development of drug resistance mechanisms implicating oxidative stress dysregulation and compromised apoptotic pathways. This study evaluates C-Phycocyanin (C-PC) as a potential adjuvant to enhance CDDP efficacy by modulating redox balance and apoptosis. Methods: GBM cells (U87 and U87-EGFRvIII) were treated with CDDP, C-PC, or their combination. Cell viability was assessed by MTT assay; apoptosis was evaluated by DAPI staining and Western blot analysis of cleaved Caspase-3 and poly (ADP-ribose) polymerase… More > Graphic Abstract

Chenglu Lu^1,#, Huiting Zhang^2,#, Ujjal K. Bhawal^3,4, Lei Wang¹, Jingwu Li¹, Pangzhou Chen^5,*, Lewei Zhu^6,*

Oncology Research, Vol.33, No.12, pp. 3657-3678, 2025, DOI:10.32604/or.2025.069703 - 27 November 2025

Abstract The tumor microenvironment (TME) is a complex network composed of non-tumor cells, extracellular matrix, blood vessels, and various molecular signals that surround and profoundly influence tumor progression. As one of the key immune effector cells within the TME, mast cells (MCs) exhibit functional complexity, and their specific roles remain widely debated. Depending on the cancer type, spatial distribution, and interactions with other TME components, MCs can demonstrate dual regulatory capabilities—either promoting or inhibiting tumor growth. This characteristic has made them an important focus in current tumor immunology research. This review aims to systematically review the More >

Yi Tang^1,2,3,4,#, Minyi Situ^1,2,3,4,#, Zhiming Wu^1,2,3,4,#, Yanjun Wang^1,2,3,4,#, Xinpei Deng^1,2,3,4, Zhicheng Liu^1,2,3,4, Shengjie Guo^1,2,3,4, Qianghua Zhou^1,2,3,4,*, Gangjun Yuan^5,*, Xingliang Tan^1,2,3,4,*, Kai Yao^1,2,3,4,*

Oncology Research, Vol.33, No.12, pp. 3973-3989, 2025, DOI:10.32604/or.2025.066184 - 27 November 2025

Abstract Background: Current chemotherapy treatments, including the TIP (Taxol, Ifosfamide, Cisplatin) regimen, have shown limited effects but strong side effects in advanced Penile squamous cell carcinoma (PSCC) patients. Trophoblast cell-surface antigen-2 (TROP-2) is a novel target for antibody-drug conjugate (ADC) drugs and has been proven to be effective in several human cancers. This study aimed to explore the biological function and potential of the ADC target in PSCC cells. Methods: A total of 196 PSCC tumor tissue specimens and clinicopathological data were collected. TROP-2 expression was detected by IHC, and the correlation between TROP-2 expression and… More > Graphic Abstract

Xuejun Guo^1,2, Yilin Fu³, Natalia Baran^4,5, Wenxue Ma^6,*

Oncology Research, Vol.33, No.11, pp. 3375-3385, 2025, DOI:10.32604/or.2025.071708 - 22 October 2025

Abstract Cluster of differentiation 47 (CD47), an immune checkpoint commonly referred to as the “don’t eat me” signal, plays a pivotal role in tumor immune evasion by inhibiting phagocytosis through interaction with signal regulatory protein alpha (SIRPα) on macrophages and dendritic cells (DCs). Although early enthusiasm drove broad clinical development, recent discontinuations of major CD47-targeted programs have prompted re-evaluation of its therapeutic potential. The purpose of this commentary is to contextualize the setbacks observed with first-generation CD47 inhibitors and to highlight strategies aimed at overcoming their limitations. Clinical challenges, including anemia, thrombocytopenia, suboptimal pharmacokinetics, and limited… More >

Raffaele Carrano^1,#, Carlotta Zucca^1,#, Nicla Cristina¹, Martina Grande¹, Eleonora Leti Maggio¹, Riccardo Bei², Antonio Infante², Chiara Focaccetti¹, Valeria Lucarini³, Loredana Cifaldi¹, Laura Masuelli⁴, Luciano Mutti⁵, Camilla Palumbo¹, Monica Benvenuto¹, Roberto Bei^1,*

Oncology Research, Vol.33, No.9, pp. 2181-2204, 2025, DOI:10.32604/or.2025.066708 - 28 August 2025

Abstract Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent advances, conventional treatment approaches remain largely ineffective due to late diagnosis, chemoresistance and immunosuppressive tumor microenvironment. This review reports the latest studies on combination therapies for mesothelioma, focusing on the potential of integrating chemotherapeutic agents, molecularly targeted agents, vaccines and natural bioactive compounds such as polyphenols. Clinical and preclinical studies demonstrate that integrating immune-modulating drugs or molecular inhibitors with chemotherapy can improve survival and reduce tumor progression in mesothelioma models and patients. Vaccine-based strategies show potential for inducing More > Graphic Abstract

ALEX A. FRANCOEUR^*, NATALIE AYOUB, DANIELLE GREENBERG, KRISHNANSU S. TEWARI

Oncology Research, Vol.33, No.7, pp. 1511-1530, 2025, DOI:10.32604/or.2025.061120 - 26 June 2025

Abstract Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy. More >

ABDUR JAMIL¹, RIMSHA SIDDIQUE², FARYAL ALTAF³, DANIYAL WARRAICH⁴, FAIZAN AHMED⁵, ZAHEER QURESHI^6,*

Oncology Research, Vol.33, No.6, pp. 1289-1300, 2025, DOI:10.32604/or.2025.058790 - 29 May 2025

Abstract Background: Male breast cancer (MBC) is a rare but significant health concern, accounting for less than 1% of all breast cancer cases. Despite its low incidence, it presents unique clinical, genetic, and psychosocial challenges. Genetic predispositions, including BRCA2 mutations and hormonal imbalances, are key factors influencing the development of MBC. However, the rarity of the condition has led to limited research and fewer treatment guidelines specifically for male patients. Methods: A comprehensive literature review was conducted using PubMed, MEDLINE, and Embase databases to identify studies focusing on the epidemiology, risk factors, clinical presentation, diagnosis, treatment,… More >

GAVIN M. ANCHONDO, KYRA PARKER, ALEXIS BRUCE, ELIZABETH CORTEZ, LE SU^*

Oncology Research, Vol.33, No.5, pp. 1001-1005, 2025, DOI:10.32604/or.2025.060573 - 18 April 2025

Abstract Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX. The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma, and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma, but emerging evidence suggests that upon depletion of SS18-SSX, an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival. In this article, we discuss the controversial roles of SS18-SSX’s transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of More > Graphic Abstract